Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) Vaults Three Cents’ Level with PR
We’ve been wondering for a while if Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) would manage to gain a level of a few cents, or sink back below the penny, but it seems EAPH is one of the longer-lasting tickers in the marijuana boom. On Tuesday, EAPH grew by nearly 60% to $0.033, on $2.06 million buying volumes, a regular level of activity in the past days. EAPH had a rapid rise in which it doubled the extremely low price, a few days of selling and a robust recovery. 
The latest email for EAPH came in at the end of January through Bull in Advantage, though surprisingly that did not end the selling. But the newest spike follows a press release stating that EAPH may be starting product sales in Mexico and Latin America. The PR uses careful language that EAPH may spread its OTC products in the US and Canada as well, but with much tighter security, this may be just a suggestion of a possibility. 
So far, there is little talk of any upcoming medical cannabis products- a step which was taken by older, better equipped marijuana companies. EAPH has a past of trying to use stem cells in experimental mode in Mexican clinics, and jumped only after mentioning an intention to integrate cannabis medication to its product range.
Investors’ forums remain highly skeptical of EAPH, despite the continued run. The company has too many red flags and not once tried to get a product through FDA approval, and so far the biggest gains have come through the latest OTC markets peak in activity. Still, there is some enjoyment in the short term, as investors utilize the energy of EAPH.
Another strong climber with a price of a few cents is Singlepoint, Inc. (OTCMKTS:SING), which exploded from a penny toward $0.08. On Tuesday, heavy selling pulled the stock down to 7 cents.
Nuvilex, Inc. (OTCMKTS:NVLX) manages to hold onto a more respectable price, and in the past few days had yet another successful run, reaching again the 20-cent level. NVLX also modified its mainstream research to include cannabis compounds in an attempt to create a viable cancer treatment. How successful this venture would be is unknown, but for now the promise is enough to put NVLX square into a portfolio aimed at adding a variety of pot stocks.
In the case of EAPH, the low price may still look like an invitation to enter, but the steep rise also means the same price may be peaking out. EAPH has shown the possibility of wiping out a substantial part of its stock, so it is best to be aware and not invest only on the optimistic drive.
